Live attenuated Listeria monocytogenes (LM) is a promising bacterial vector able to induce a T-cell response to tumor-associated antigens and demonstrates great potential for use in vaccine development. A novel recombinant LM-based vaccine (Lmdd (LM DdalDdat)-MPFG (multiple peptide fusing genes)) was developed with the ability to express and secrete hepatocellular carcinoma (HCC)-related tumor-associated antigens fragments due to the insertion of hepatitis B virus (HBV)-X protein (HBx)-derived epitopes HBx 52À60 and HBx 140À148 , the universal T-helper epitope, alpha-fetoprotein (AFP) epitope AFP 158À166 , and melanoma antigen gene (MAGE)-3 271À279 into the HBV core protein. Following immunization with the Lmdd-MPFG vaccine, macrophages exhibited uptake of the bacteria; the vaccine was then nearly cleared 3 days after the first administration. It disappeared even more quickly following subsequent vaccinations. However, recombinant Lmdd-MPFG allowed for the full development of an antitumor response towards the human leukocyte antigen (HLA)-A0201 epitopes of MPFG. Each epitope stimulated an augmented T-cell proliferation and enhanced the supernatant level of interferon (IFN)-c in vitro. In addition, IFN-c-producing CD8 þ T cells as well as in vivo cytolytic activity were significantly increased in HLA-A2 transgenic mice. Additionally, the Lmdd-MPFG developed a strong antitumor response, as indicated by the significant resistance of immunized mice to MPFG-positive Hepa1-6 cell challenge in both a prophylactic and therapeutic setting. Tumor regression was accompanied by an enhanced cytotoxic T lymphocyte response and a decrease of regulatory T cells in the tumor. Collectively, these results suggest that utilizing attenuated LM as a vaccine vector, able to carry the MPFG gene, presents a potentially feasible strategy for prevention of HCC.
Introduction
Hepatocellular carcinoma (HCC) is a malignancy that is among the leading causes of cancer-related death globally. The prevalence of HCC is over 100 per million in the Chinese population, in which hepatitis B viral infection is endemic (Hussain et al., 2001; Sanyal et al., 2010) . HCC has a very poor prognosis and rarely responds to conventional treatments such as surgery, radiation, or chemotherapy (Kim et al., 1991; Ritter et al., 2004) . Alternative options such as percutaneous intratumoral ethanol injection, transarterial chemoembolization and radiofrequency thermal ablation are reserved for palliative therapy (Badvie, 2000; Lin et al., 2005) . Following successful cases in other types of malignancies, immunotherapeutic strategies hold great promise for lowering recurrence and improving recurrence-free outcome after surgery for HCC Ritter et al., 2004; Greten et al., 2010) . As for other antitumor immunotherapies, identification of the tumor-specific antigens able to induce specific antitumor cellular immunity is critical in HCC.
One of the most effective methods to induce a CD8 þ cytotoxic T lymphocyte (CTL) response against a given tumor antigen is to utilize a live, intracellular vector. Listeria monocytogenes (LM) has a very typical intracellular life cycle that makes it an excellent model for the induction of a protective cellular immune response (Mackaness, 1969) . As an intracellular parasite, LM has direct access to the cytoplasm of antigen-presenting cells such as macrophages and dendritic cells. The antigenpresenting cells infected by LM, which carries foreign antigen genes, present foreign antigens with both major histocompatibility complex (MHC) class I and MHC class II molecules efficiently, thus inducing both a CD8 þ and CD4 þ antigen-specific T-cell response (Shedlock et al., 2003; Souders et al., 2006; Skoberne et al., 2008) . Another important feature of LM is the hemolytic activity of listeriolysin O, which has a critical role in allowing the bacterium to be effectively targeted by the cellular immune system (Gedde et al., 2000) . It perforates the phagosomal membrane, allowing the bacterium to escape the vacuole and enter the cytoplasm. This relatively fast and effective targeting and clearance of the bacterium by the cellular immune system makes LM a safe, live vector in comparison with other intracellular vectors (Pamer et al., 1997) . As a vaccine vector, LM is also able to infect the host when administered orally, thus making it simple to administer (Peters and Paterson, 2003; Li et al., 2008; Spears et al., 2008) . All of these properties have been explored to develop an effective Listeria-derived live vaccine, suitable for experimental and clinical studies. So far, LM has been used as an intracellular facultative bacterium with properties suitable for immunotherapy, utilizing live vaccine vector for tumors or infectious diseases such as HIV (Frankel et al., 1995; Yoshimura et al., 2006 Yoshimura et al., , 2007 .
To avoid serious toxicity due to LM, we based the present studies on a highly attenuated vaccine vector, referred to as Lmdd (LM DdalDdat), in which essential genes in the D-alanine (D-ala) synthesis pathway, alanine racemase (dal) and D-amino acid aminotransferase (dat) genes, have been deleted. Lmdd exhibits minimal toxicity and only modest immunogenicity (Thompson et al., 1998; Friedman et al., 2000; Wallecha et al., 2009) . As with any antitumor immunotherapy, in HCC, it is critical to select a T-cell epitope combination that can induce strong and specific antitumor cellular immunity. We, therefore, generated a new chromosomal LM recombinant epitope that expresses the fusion peptide MPFG (multiple peptide fusing genes), a combination of HCC-related human leukocyte antigen (HLA)-A0201 epitopes, including full-length hepatitis B virus (HBV) core protein (HBc), HBV-X protein (HBx) 52À60 , HBx 140À148 , alpha-Fetoprotein (AFP) 158À166 and melanoma antigen gene-A (MAGE) 271À279 . These epitopes have been reported to be highly effective CTL inducers in HCC immunotherapies Zhou et al., 2005; Kong et al., 2007; Song et al., 2007; Ding et al., 2009) . These epitopes target several immunodominant regions of the HBV-related HCC, following a single administration of the vaccine. In the present study, administration of the vaccine exhibited minimal toxicity and induced CD8 þ anti-HCC T-cell responses in a MHC restrictive pattern in mice. Infection with the vaccine increased the duration of survival of the HCC bearing transgenic (Tg) mice and retarded the growth of the tumor. A disruption of immune tolerance was also observed in the tumor microenvironment, with a decrease in the abundance of regulatory T (Treg) cells. Our studies have demonstrated that this attenuated Listeria vaccine enhances antitumor activity and modulates Treg cells, which makes it a promising candidate for anticancer immunotherapy.
Results

Construction of recombinant Listeria strains secreting MPFG fusion proteins
The recombinant LM strain Lmdd-MPFG was designed to express and secrete a fusion peptide containing full-length HBc, HBx 52À60 , HBx 140À148 , AFP 158À166 , MAGE 271À279 and flag tag (Figure 1a) . These peptides are all HLA-A0201-restricted epitopes. The LmddAnnexin A2 (A2) was constructed as a control. The fusion peptide gene was cloned into a new derivative (p1565) of a LM plasmid PKSV7 (Smith and Youngman, 1992) , as recently described (Li et al., 2008; Sciaranghella et al., 2011) . The MPFG fusion peptide gene or A2 gene was cloned in frame with the LM Phly promoter-signal sequence (32 amino acids long) of the gene that expresses listeriolysin O when intact (Figure 1b ). The target genes were then introduced into the chromosome within the LM sepA gene of Lmdd by allelic recombination. As this plasmid carries no antibiotic-resistant genes in the chromosome insertion segment, the dal gene of Bacillus subtilis is used to allow for selection of recombinants (Sciaranghella et al., 2011) . The resulting recombinant organisms are thus plasmid-free and antibiotic-resistant genefree ( Figure 1c ). In mice, these bacteria are significantly attenuated and exhibit a systemic LD 50 of B0.5-1.0 Â 10 8 (vs wild-type LD 50 B10
4
) and survive for only approximately 3 days after infection (Li et al., 2008) . The expression and secretion of this fusion peptide was tested in culture supernatants by western blot, using an anti-flag polyclonal antibody. Thus, MPFG and A2 were shown to be 29 and 55 KDa, respectively ( Figure 1d ). The recombinant Lmdd-MPFG strain was stable and retained the expression of MPFG after 20 generations in vivo (Supplementary Information and Supplementary Figure S1 ).
The in-vivo infectivity and distribution of Lmdd-MPFG vaccine First, we compared the infectivity of Lmdd-MPFG and Lmdd-A2. After intravenous Lmdd injection, peritoneal macrophages were collected as Williams et al. (2010) and Shen et al. (2010a, b) described. The abdomens of the mice were gently massaged after injection with 5 ml sucrose, and the lavage fluid was withdrawn by an 18-gauge needle inserted along the midline. The cells were resuspended and plated into six-well plates and cultured for 2 h after spinning. Non-adherent cells were removed. The intracellular growth was monitored for 8 h by taking duplicate samples every other hour from the macrophage cells, followed by titration of the bacteria on brain heart infusion agar (Difco Laboratories, Detroit, MI, USA) and measuring colony forming units (CFU). There is no significant difference between Lmdd-MPFG or A2 strains (Figure 2a) , suggesting that the construct and modification of the vaccine would not significantly change the infectivity. To investigate the in vivo distribution of the Lmdd-MPFG vaccine, organs indicated were assessed on subsequent days in groups of mice (n ¼ 3) for the presence of viable bacteria by plating dilutions of homogenized tissues on brain heart infusion agar plates (Kursar et al., 2002; Zhao et al., 2005) . The spleen exhibited the greatest amount of bacteria (3.33 Â 10 4 ± 1.12 Â 10 4 CFU/g), followed by the liver (0.4 Â 10 3 ±1.62 Â 10 3 CFU/g) and lung (1.90 Â 10 2 ± 1.82 Â 10 2 CFU/g) on day 1 after the first vaccination. There were no bacteria detected in the brain. The amount of live bacteria decreased sharply after the subsequent vaccination (Figure 2b ). This result suggests that most of the Lmdd vaccine was taken up by phagocytes in the spleen and liver, and that multiple immunizations can induce an immune response in the mice, leading to a rapid clearance of the bacteria. EM analysis indicated that the Lmdd-MPFG vaccine infected the spleen and liver in vivo with high efficiency. As shown in Figure 2c , we clearly found the Lmdd bacteria in the spleen and liver of the infected mice. Haematoxylin and eosin staining of the indicated tissue sections demonstrated that the immunized group exhibited only mild evidence of an inflammatory response with no structural damage and necrosis (Figure 2d ). These results confirm that our Lmdd-MPFG vaccine can infect multiple organs via the intravenous pathway.
Lmdd-MPFG can induce antigen-specific T-cell immune responses To investigate the immunological effects of the Lmdd-MPFG vaccine against various peptides, we conducted a series of experiments including: T-cell proliferation assay, level of interferon (IFN)-g secretion, intracellular IFN-g staining and in vivo cytotoxicity (CTL) assay. The splenocytes isolated from the mice infected with Lmdd-MPFG or the control groups were co-cultured with various amounts of specific peptides to measure proliferation by the level of 3 H incorporation. As shown in Figure 3a , the splenocytes from the Lmdd-MPFGinfected group exhibited the highest stimulation index monocytogenes were demonstrated by western blot analysis of the proteins using trichloroacetic acid-precipitated cell culture supernatants. Fusion proteins were detected using a polyclonal anti-flag antibody. Lmdd and Lmdd-A2 were used as controls.
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Y Chen et al (9.29 ± 2.05) in comparison with the control groups (2.26±1.21), when co-cultured with the HBx 52À60 peptide. The culture supernatants were collected for IFN-g measurement after 3 days of co-culture with specific peptides. Figure 3b shows that the splenocytes from the immunized group secreted the largest amount of IFN-g (1221.62 ± 80.64 pg/ml). These results indicate that Lmdd-MPFG can induce a specific CD4 þ and CD8 þ T-cell response against the MPFG epitopes. To determine whether the immune cells exhibited a response to each of the epitopes, we assessed the in-vitro MPFG-specific cytotoxicity of the CTLs against target cells using the lactate dehydrogenase release assay (Chen et al., 2009 Figure 3c ).
To assess whether CD8 þ T cells produce IFN-g in response to a specific HLA-A 0201 peptide, cells were stained for CD8 and intracellular IFN-g. As shown in Figure 4b , CD8 þ T cells isolated from HLA-A2 Tg mice immunized with Lmdd-MPFG produced far greater amounts of IFN-g in response to their specific peptides, compared with the CD8 þ T cells from the control animals. These results indicated that the Lmdd-MPFG vaccine induced a functional and specific CD8 þ T-cell response. To confirm whether these epitopes are recognized by specific T cells in vivo, we measured the in vivo cytolytic activity of the immunized mice. 7 CFU of Lmdd-MPFG or A2 strains. The intracellular growth was monitored for 8 h by removing cells every other hour from three mice per group, followed by titration of the bacteria on brain heart infusion agar plates. (b) Listeria was injected intravenously into mice weekly for a total of 3 weeks. Organs indicated were assessed on subsequent days in groups of mice (n ¼ 3) for the presence of viable bacteria by plating dilutions of homogenized tissues on brain heart infusion agar. The plates were incubated at 37 1C for 24-48 h for bacterial growth. Data are presented as mean CFU ± s.e.m. (c) Electromagnetic analysis shows the high efficiency in which Listeria infected the spleen and liver in vivo, as shown here after one immunization with Lmdd-MPFG. Black arrows, Lmdd bacteria. (d) The effects of attenuated Listeria infection in mice detected by haematoxylin and eosin staining. Immunized mice were killed 3 days after the first inoculation and indicated organs (liver and spleen) were obtained. Small vascular proliferation and vacuolization in a few hepatocytes were observed in liver tissue. However, rims of hepatocytes around a central vein remained intact. No proliferation or apoptosis were seen in the hepatocytes of the immunized mouse. The spleens were slightly swollen without necrosis or structural damage. Representative photomicrographs indicated the mild congestion and infiltration by macrophages containing phagocytized contents in spleen tissue. These pictures are representative of three mice examined in vaccinated and normal groups. Arrows indicate inflammatory sites.
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The results indicated that the Lmdd-MPFG group exhibited the highest cytolytic activity (71.5 ± 0.15%) against HBx 140À148 -loaded target cells versus the (16.1 ± 0.06%) cytolytic activity found in naı¨ve mice, (21.4 ± 0.08%) in mice immunized with Lmdd-A2.
To determine whether this cytolytic activity was indeed dependent on the function of CD8 þ T cells, Lmdd-immunized mice were depleted of either CD4 Figure S2 ). The results demonstrated that immunized mice injected with control rat immunoglobulin showed 84-91% cytolysis of HBx 140À148 peptide-labeled targets, 18 h following target cell injection. Depletion of CD8 þ T cells resulted in the loss of most of this activity, whereas depletion of CD4 þ T cells had little effect. These results indicate that MPFG-specific CD8 þ T cells, induced by Lmdd-MPFG vaccine vectors, but not the control vectors, are responsible for the in-vivo activity.
cells (Figures 4c and d and Supplementary
In addition, to test whether the Lmdd-MPFG vaccine is also able to induce T-helper (Th)2/antibody-mediated responses, we performed enzyme-linked immunosorbent assay (ELISA) for MPFG-specific antibodies, as well as interleukin (IL)-4 and IL-10 enzyme-linked immunosorbent spot (ELISPOT) assays. The serum samples were collected from the Lmdd-MPFG, Lmdd-A2, Lmdd or untreated group (n ¼ 10), 1 week following the last vaccinations. Only 2 of 10 Lmdd-MPFG-immunized mice exhibited increased anti-HBc antibody levels. However, there was no significant difference in absorbance readings among these groups. Additionally, an appreciable level of Abs against various peptides of MPFG was not detected by the peptide ELISA (Shen et al., 1999; Blasco et al., 2007) . Moreover, IL-4 and IL-10 production were not elevated in all of the groups by ELISPOT analysis (Supplementary Figure S3) .
Lmdd-MPFG vaccines caused regression of established Hepa1-6 tumors in mice To study the prophylactic and therapeutic effects of the Lmdd-MPFG vaccine, HLA-A2 Tg mice were inoculated subcutaneously with Hepa 1-6/HLA-A2/MPFG tumor cells 3 days after or 7 days before immunization to establish a tumor-bearing model. Animals received an intravenous immunization with either Lmdd-MPFG or control vaccine. Immunizations were repeated two additional times at 1-week intervals. In both the prophylactic model and therapeutic tumor murine model, Lmdd-MPFG vaccination was able to significantly slow down 5a and c) . In evaluating the survival of the prophylactic and therapeutic study mice (Figures 5b and d) , the mice achieved approximately 25% greater long-term, tumorfree survival.
The tumor infiltrated lymphocyte (TIL)-specific response to the MPFG epitopes We initially isolated the TILs from the prophylactic and therapeutic tumor models immunized with Lmdd-MPFG or control vaccines. To evaluate whether the TILs exhibit a specific response to the HLA-A0201 peptides, we used the sorted CD8 þ TILs to detect IFN-g secretion by ELISPOT. The ELISPOT results demonstrated that subsequent to incubation with the peptides, the CD8
þ TILs from the Lmdd-MPFG groups exhibited a greater number of IFN-g secreting spots, compared with the control groups (Figure 6a ). These results indicated that the Lmdd-MPFG vaccine can induce a functional and specific CD8 þ T-cell response. To confirm this finding, we measured the cytolytic activity of TILs in both tumor models. The results indicated that the Lmdd-MPFG group exhibited the highest level of cytolytic activity against target cells loaded with variant peptides in both of the prophylactic model and therapeutic model (Figure 6b) .
The phenotypic characteristics of TILs were also determined in tumor-bearing mice. To confirm the effect of the Lmdd vaccine on Treg cells, lymphocytes harvested from TILs of each groups were stained with anti-CD4, CD25 and Foxp3 antibodies. The lymphocytes from the TILs in Lmdd-MPFG vaccine groups had fewer CD4 þ CD25 þ Foxp3 þ cells when compared þ T cells in vivo. 5,6-carboxyfluorescein diacetate succinimidylester (CFSE)-labeled syngeneic splenocytes pulsed with HBX 140À148 peptide (CFSE high ) or not (CFSE low ) were injected intravenously into immunized mice. T-cell depletion of effector mice was achieved upon two administrations (0.5 mg each; intraperitoneally) of anti-CD8 (clone GK 2.43) or anti-CD4 (clone GK 1.5) rat anti-mouse mAbs or control rat immunoglobulin. The depleting Abs resulted in 99% removal of the respective T cells, whereas control rat immunoglobulin had no effect on these cell populations. MPFG-specific killing of HBX 140À148 -positive targets was measured by flow cytometry. Representative examples of in-vivo killing of HBX 140À148 targets are shown. (d) Cytolytic activity in different regimens in immunized mice.
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with the untreated group (13.11 ± 3.06% prophylactic model, 11.27 ± 4.26% therapeutic model and 22.63 ± 7.58% no treatment; Figure 7a) . A similar pattern was also found concerning the immunohistochemistry of the excised tumor tissues (n ¼ 5), which confirmed a lower positive staining level of Foxp3 in the vaccinated group in comparison with that of the control mice (Figure 7b) (Figure 7c ). However, a higher percentage of CD4 þ CD25 þ T cells were positive for migration and lymph node homing receptors CCR7 and CD62L from the control group than from the vaccinated group. Notably, another important chemokine receptor, CCR4, was found on the majority of the CD4 þ CD25 þ T cells in the normal controls, but was found on only 40% of CD4 þ CD25 þ T cells from vaccinated group. Moreover, 30 to 50% of the CD4 þ CD25 þ T cells in the TILs from the control group were IL-10 þ and tumor growth factor (TGF)-b þ (Figure 6c ), whereas only few in the vaccinated group (Po0.01) were positive. These data indicate that some considerable phenotypic differences exist between the CD4 þ CD25 þ populations in the TILs of the vaccinated group versus the normal controls.
Discussion
Immunotherapy holds great promise as a therapy with the potential to be used in combination with surgery and other traditional treatments. With the continuing development of immunology and molecular biology, engineered bacterial vaccines can be designed and tested to suit specific purposes. HBV-associated HCC has a very poor prognosis along with limited effective treatment options (Duvoux, 1998; Sanyal et al., 2010; Bai et al., 2011) ; thus, we have investigated this novel approach in a disease model system.
It has been shown that eliciting a tumor-specific T-cell response is the most critical and challenging aspect of any effective anti-HCC immunotherapy. In the past decade, a large body of studies have demonstrated that a live-attenuated LM vector can induce both CD4 þ and CD8 þ T-cell responses without causing harmful toxicity when used in an animal model or clinical study (Shedlock et al., 2003; Souders et al., 2006; Skoberne et al., 2008; Seavey et al., 2009; Wallecha et al., 2009) . It is widely understood that Listeria is rapidly taken-up by immune cells such as dendritic cells and macrophages upon entering the host. Because of this particular dual intracellular pathway, the bacterium can access both phagosomal and intracellular compartments. Consequently, antigen expressed by the LM-based vaccine can be presented on both MHC class I and II molecules. As a result, the cellular immune response elicited against these antigens includes both CD4-positive and CD8-positive T cells. This unique life style makes LM an (Alouf, 2000; Pamer, 2004; Singh and Paterson, 2006) . For clinical application of the vaccine, safety is the primary concern. Lmdd is a hyperattenuated, double deletion of LM that lacks D-alanine racemase (dal) and D-amino acid aminotranferase (dat). It is unable to synthesize D-alanine, an absolutely essential molecule needed for the construction of the bacterial cell wall, and thus for bacterial viability (Thompson et al., 1998) . As a vaccine, Lmdd is extremely attenuated and can be used only if D-alanine is supplied exogenously, thus resulting in weak immunity. To make the vector stronger (but still maintain a high degree of attenuation), we introduced the dal gene of B. subtilis (Li et al., 2008) to partially complement the LM dal deletion, which also allowed us to select chromosomal MPFG recombinants in the absence of drug-resistance genes. The result is a recombinant, drug-resistance gene-free and plasmid-free bacterium that can grow well without added D-alanine, but remains significantly attenuated, thus surviving in mice for only approximately 3 days, but nonetheless able to generate a good immune response. The LD 50 is approximately 0.5-1 Â 10 8 versus a wild-type LD 50 of 1 Â 10 4 (data not shown). In this study, the Lmdd vaccine exhibited minimal toxicity during the first 3 days after infection in the HCC bearing mouse model and was found in the spleen, liver and other tissues without causing an apparent inflammatory response and tissue damage. Similarly, oral infection in non-human primates using a vaccine dose over 10 5 times higher than used here resulted in no distress, diarrhea, sepsis or other clinical symptoms (Sciaranghella et al., 2011) .
The selection of tumor-associated epitopes is also very important to create an effective vaccine. In this study, we selected a multi-epitope peptide combination to induce HLA-A0201 restrictive T-cell responses. HBVassociated peptides, such as HBx 52À60 , HBx 140À148 , and the epitope of HCC high-expressing protein, Figure 6 The TIL functional analysis. The TILs were isolated from excised tumor samples from both of the prophylactic and therapeutic groups as described in the Supplementary Materials and methods section. (a) ELISPOT assay of TILs from Tg mice. TILs from vaccinated Tg mice were harvested 6 days after the final vaccination with the Lmdd-MPFG, and standard IFN-g ELISPOT assays were then developed according to the kit manual. Mice vaccinated with Lmdd-MPFG demonstrated significantly more spot-forming colonies than controls (*Po0.05, **Po0.01). (b) Cytotoxicity of the TILs against target cells loaded with various peptides. Target cells were prepared by using T2 cells pulsed with or without HBX 140À148 peptide (5 mg/ml) in cell culture medium or tumor cell lines (K562) for 2 h, followed by three consecutive washes. For the assay, effector cells (restimulated CD8 þ T cells from TIL after incubation with HBX 140À148 peptide overnight) and target (peptide-pulsed T2 or tumor cells) were incubated in a 0.2-ml culture volume of a 96-well culture plate at a ratio of E:T ¼ 1:5, 1:25 and 1:50. The cells were co-cultured for 18 h and the supernatant was then harvested. Significant differences are indicated as determined by the Student's t-test. **Po0.01. The lactate dehydrogenase levels were measured following the kit protocol as described in the Supplementary Materials and methods section.
Listeria-based vaccine against HCC Y Chen et al AFP 158À166 , MAGE 271À279 , and the full length of HBc were cloned into the Lmdd vector. The HBV core has been previously exploited to serve as a carrier for foreign epitopes (Furukawa et al., 2004; Ding et al., 2009) . The core particles can drastically improve the immunogenicity of foreign protein segments presented on the surface 
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Y Chen et al (Bertoletti et al., 1993) . Moreover, many studies have reported that HBc itself contains potential CTL-inducing epitopes that have been exploited (Song et al., 2007; Ding et al., 2009) . HBx is a multifunctional regulatory protein expressed at a higher ratio than preS2/S, HBc and HBV surface protein in HCC (Kim et al., 1991; Cheng et al., 1997; Su and Schneider, 1997; Su et al., 1998) . Because HBx was dominantly expressed in hepatitis and hepatoma tissues, it has been identified as a suitable target for immunotherapy (Ding et al., 2009) . In this study, we chose HBx 52À60 and HBx 140À148 , two HLA-A0201 epitopes to stimulate HCC specific CTLs. AFP is also a potential target for immunotherapy in HCC (Ritter et al., 2004; Greten et al., 2010) . We selected HLA-A0201 restrictive epitope hAFP 158À166 in this study to make the fusion peptide. It has been previously demonstrated that this epitope consistently elicits cytokine production and cytotoxicity Butterfield et al., 2001; Kong et al., 2007) . MAGE-A is a multi-gene family that consists of 12 homologous genes (MAGE-A1-A12).
In accordance to the work of Zerbini et al. (2004) , we chose a CTL epitope (MAGE 271À279 ) that could generate an HLA-A0201-restricted CTL response against HCC. Covering a wider range of epitopes to reduce the chance of tumor escape has been proven to be effective. Thus, in this study, we generated a fusion peptide that covers five peptides or epitopes that all of which have been shown to exhibit a specific T-cell anti-HCC response.
The results presented here demonstrated that the Lmdd accumulate in peripheral lymph tissues and cells, express the fusion peptide and induce a strong and protective immune response. When carrying the fusion peptides of MPFG, the vector is able to elicit a T-cell response against each of the various epitopes simultaneously. The resulting T cells showed enhanced replication and production of IFN-g. Importantly, an in vivo cytotoxicity study demonstrated that the stimulated T cells can lyse target cells loaded with each peptide in an antigen-specific manner. Thus, when carrying fusion peptides, Lmdd is able to elicit a T-cell response against various epitopes simultaneously. In HCC patients, it has been demonstrated that a deviation to a Th2 immune response occurs (Nieters et al., 2005) . In our Tg animals, vaccination with Lmdd-MPFG led to a shift in the Th1/Th2 balance toward a Th1 dominant immune response, as demonstrated by the increased secretion of the Th1 cytokine IFN-g in the stimulated splenocytes by ELISA and ELISPOT assays. Meanwhile, no significant Th2/antibody-mediated immune response was induced. These findings indicated that a Th1 rather than Th2 immune response has a critical role in Lmddmediated anti-tumor immunotherapy. Taken together, the ability of this vaccine to generate a Th1 response makes the vaccine an attractive candidate for clinical trials for HCC, in which the shift into a dominant Th2 response is of concern.
Significantly, the Lmdd-MPFG vaccine was able to prevent tumor growth in a prophylactic model. It was also effective therapeutically, and induced regression of transplanted tumors and elongated the survival of tumor bearing animals. The in vivo cytolysis model for such protection is shown in Figure 5 . The CD8 þ T cells isolated from TILs exhibited a strong immune response against the specific epitopes targeted.
The suppression of Tregs in the TIL population is another intriguing finding of this LM vaccine-based study. CD4 þ CD25 þ Foxp3 þ Treg has been demonstrated to be a negative factor in the prognosis for many tumors, including HCC (Zhou et al., 2010; Shen et al., 2010a, b) . In a previous LM-based vaccine study, depletion of Tregs by either anti-CD25 or cyclophosphamide treatment enhanced the antitumor effects of the vaccine (Yoshimura et al., 2007) . Using Lmdd-MPFG vaccine, we found a significant decrease of Foxp3 þ Tregs in the TIL population. This potentially explains the rapid tumor regression observed in the Lmdd-MPFG-treated group. This finding suggests a possibility that an LM-based specific vaccine may suppress Treg recruitment or differentiation. To elucidate the mechanism of the finding, we initially studied the Treg phenotype in TILs of Lmdd-MPFG vaccinated tumor-bearing mice. The expression of functional Treg molecules (such as GITR, ICOS and CTLA-4) serves as confirmation that this group of Tregs are phenotypically similar to Tregs commonly reported (Yamamoto et al., 2006; Menetrier-Caux et al., 2009) . These Tregs may either originate from Tregs recruited by chemotaxis or from the newly differentiated Tregs originating from naı¨ve T cells in TILs. It has been previously suggested that LM immunization leads to a decrease in CCR4 expression, a very important chemokine that attracts Treg from circulation into tumor sites (Olkhanud et al., 2009) . In this study, we checked chemokine receptor expression of the Treg in TILs. The TILs of the immunized group showed a significantly decreased expression of chemokine or receptors such as CD62L, CCR4 and CCR7. These results supported the finding that LM vaccination inhibits Treg recruitment into tumor sites and that chemotaxis may have an important role in lowering the Treg number in TILs. We observed a decreased level of IL-10 and TGF-b expression in the Tregs of the TILs in the vaccinated group. IL-10 and TGF-b are two critical functional Treg cytokines that inhibit the antitumor responses directly. More importantly, the secreted TGF-b induces the differentiation of even more naı¨ve T cells into Treg in tumor microenvironment. This may also contribute to the decreased numbers of Tregs in TILs in the immunized group. Taken together, these results strongly suggest that Lmdd-MPFG vaccination decreases Tregs in TILs by inhibiting both recruitment of Tregs to the tumor site and production of Treg inducing cytokine, TGF-b and IL-10.
In conclusion, the Lmdd-MPFG vaccine was able to overcome self-tolerance to an endogenous tumorassociated protein, induced tumor regression in a foreign antigen model, and slowed the development of HCC. The strength of this vaccine warrants further investigation into its potential clinical application for HCC.
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Materials and methods
Materials
The oligonucleotides and peptides were synthesized by Invitrogen (Carlsbad, CA, USA), and the DNA sequencing was performed by Genescript Inc. (Nanjing, China). The peptides used in this study were as follows: HBC 118À126 (LLW FHISCL), HBC 141À149 (YLVSFGVWI); HBX 140À148 (VLH KRTLGL), HBX 52À60 (CLLKDWEE); Th (KFVAAWTL); AFP 158À166 (FMNKFIYEI); MAGE 271À279 (FLWGPRALV); EBV-LMP2A 426À434 (CLGGLLTMV). All peptides are HLA-A*0201-restricted CTL epitopes.
Mice and tumor cell lines
Breeding pairs of HLA-A2 Tg mice with a C57Bl/6 background were purchased from the Model Animal Research Center of Nanjing University. Six to eight-week-old Tg mice were used at the start of the experiments.
Hepa1-6, a mouse hepatoma cell line derived from C57Bl/6 mice, was purchased from the American Type Culture Collection. The cell lines are stably expressing with either HLA-A2 or both transformed with the MPFG genes. Cells were maintained in Dulbecco's modified Eagle medium supplemented with 10% heat-inactivated FCS (Gibco, Carlsbad, CA, USA), 2 mM Lglutamine, 100 U/ml penicillin, 100 mg/ml streptomycin and 400 mg/ml G418 (Sigma, St Louis, MO, USA). 0 -TAAGACAGGACTACCCGCTAACATT GAGATTCC-3 0 . The fragment was ligated into a p1565 plasmid, which contains a dal gene and promoter of B. subtilis, and fused to the listeriolysin O signal sequence, whose expression is driven by the phly promoter. The recombinant plasmid was electroporated into the LM Ddal Ddat strain with forced insertion into the sepA site on the chromosome at 42 1C. Positive clones were screened on brain heart infusion agar plates supplemented with 20 mg/ml chloramphenicol. Both strains are attenuate and have similar LD 50 in mice at 10 7 CFU compared with the parental wild-type strain 10403s.
Construction of Lmdd-MPFG vaccines
Mouse immunization and tumor challenge
Six to eight-week-old HLA-A2 Tg mice were immunized, intravenously with 0.1 Â LD 50. of viable LM in 0.2 ml of phosphate-buffered saline, weekly for a total of three weeks. Mice immunized with phosphate-buffered saline or Lmdd-A2 were used as a control. On day 26, spleens were isolated for cellular immune response measurements in vitro. To determine the effect of the vaccine as a tumor therapy in a prophylactic setting, 3 days after the first immunization, mice were challenged by a subcutaneous injection in the flank with 5 Â 10 4 syngeneic MPFG-positive Hepa1-6 cells. In a therapeutic setting, HLA-A2 Tg mice were first challenged with 5 Â 10 5 syngeneic MPFG-positive Hepa1-6 cells for 7 days, followed by three immunizations as described earlier in this section at 1-week intervals. Tumor diameter was measured by calipers twice per week and recorded as the mean of narrowest and longest surface length for each animal in the group. Mice were killed when the tumor size reached a 20 mm average diameter. Each experiment was performed at least twice and results were essentially similar unless described otherwise.
Detailed informations about some experiments including ELISA, western blot, T-cell proliferation assay, flow cytometry, cytotoxicity assay, ELISPOT assay, isolation of TILs and immunohistochemistry are provided in the Supplementary Materials and methods.
Statistical analysis
Data are expressed as mean±s.e.m. as indicated in each experiment. And the comparisons between the groups were made by one-way ANOVA followed by unpaired t-test. A 4.0 version (2005) of the GraphPad Prism software (Graphpad software Inc., San Diego, CA, USA) was used for this purpose. Values of Po0.05 were considered significant. Survival curves were estimated using the Kaplan-Meier method, and significance was assessed using the log-rank or the w 2 -test.
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